SC
CRSP icon

Slow Capital’s CRISPR Therapeutics CRSP Stock Holding History

Slow Capital’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.07M Buy
92,894
+1,671
+2% +$88.1K 0.59% 61
2026
Q1 		$4.34M Buy
91,223
+14,593
+19% +$770K 0.56% 57
2025
Q4 		$4.02M Buy
76,630
+3,343
+5% +$200K 0.48% 62
2025
Q3 		$4.75M Sell
73,287
-2,109
-3% -$121K 0.56% 54
2025
Q2 		$3.67M Buy
75,396
+10,152
+16% +$393K 0.45% 66
2025
Q1 		$2.22M Buy
65,244
+3,669
+6% +$156K 0.3% 84
2024
Q4 		$2.42M Sell
61,575
-24,335
-28% -$1.15M 0.34% 84
2024
Q3 		$4.04M Buy
85,910
+6,694
+8% +$340K 0.62% 50
2024
Q2 		$4.28M Buy
79,216
+11,647
+17% +$674K 0.69% 38
2024
Q1 		$4.61M Buy
67,569
+933
+1% +$66.8K 0.74% 34
2023
Q4 		$4.17M Buy
66,636
+408
+0.6% +$22.6K 0.73% 34
2023
Q3 		$3.01M Buy
66,228
+2,405
+4% +$124K 0.55% 51
2023
Q2 		$3.58M Sell
63,823
-2,879
-4% -$163K 0.62% 42
2023
Q1 		$3.02M Buy
66,702
+2,225
+3% +$108K 0.56% 57
2022
Q4 		$2.62M Buy
64,477
+20,295
+46% +$1.08M 0.58% 57
2022
Q3 		$2.89M Sell
44,182
-1,036
-2% -$75.1K 0.62% 37
2022
Q2 		$2.75M Buy
45,218
+2,886
+7% +$170K 0.67% 43
2022
Q1 		$2.66M Buy
42,332
+12,035
+40% +$756K 0.5% 61
2021
Q4 		$2.3M Buy
30,297
+11,629
+62% +$1.02M 0.39% 91
2021
Q3 		$2.09M Buy
18,668
+54
+0.3% +$6.78K 0.38% 91
2021
Q2 		$3.01M Buy
18,614
+2,227
+14% +$271K 0.57% 61
2021
Q1 		$2.37M Buy
16,387
+87
+0.5% +$13.1K 0.51% 73
2020
Q4 		$2.5M Buy
16,300
+280
+2% +$33.1K 0.6% 51
2020
Q3 		$1.34M Buy
16,020
+2,977
+23% +$264K 0.36% 103
2020
Q2 		$959K Buy
13,043
+130
+1% +$7.6K 0.28% 110
2020
Q1 		$548K Sell
12,913
-3,611
-22% -$186K 0.21% 119
2019
Q4 		$1.01M Buy
16,524
+3,462
+27% +$189K 0.31% 104
2019
Q3 		$535K Sell
13,062
-175
-1% -$8.36K 0.19% 125
2019
Q2 		$623K Sell
13,237
-248
-2% -$9.91K 0.26% 112
2019
Q1 		$482K Buy
+13,485
New +$466K 0.19% 128

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Slow Capital's CRSP Position: Q2 2026 in Review

Slow Capital increased its CRISPR Therapeutics (CRSP) stake by 1.8% in Q2 2026, buying an estimated $88.1K and bringing the position to 92,894 shares worth $5.07M. The position accounts for 0.59% of the portfolio, ranked #61.

Slow Capital first reported a position in CRSP in Q1 2019 and has held it in 30 quarters since. 522 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • Slow Capital held 92,894 shares of CRISPR Therapeutics worth $5.07M as of Q2 2026.
  • Slow Capital bought 1,671 CRISPR Therapeutics shares in Q2 2026, an estimated $88.1K.
  • CRISPR Therapeutics made up 0.59% of Slow Capital's portfolio in Q2 2026, its #61 holding.
  • Slow Capital first reported a position in CRISPR Therapeutics in Q1 2019 and has held it in 30 quarters since.
  • 522 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on Slow Capital's 13F filing for Q2 2026, filed 22 Jul 2026.